Latest News and Press Releases

Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.

Longeveron raises $4.4 Million in gross proceeds from warrant exercise transaction to fund development of its cellular therapy Lomecel-B

Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.

Longeveron to Present at the Emerging Growth Virtual Conference

Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.

Longeveron to attend BIO 2024, exploring potential partnership and strategic opportunities for its Alzheimer’s disease program.

Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.

Longeveron announces planned transitions on its Board of Directors.